Your browser doesn't support javascript.
loading
Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.
Luo, Hong-Yu; Gao, Li-Chen; Long, Hui-Zhi; Zhou, Zi-Wei; Xu, Shuo-Guo; Li, Feng-Jiao; Li, Hong-Li; Cheng, Yan; Li, Cai-Xia; Peng, Xing-Yu; Li, Liang; Chen, Ran; Deng, Ping.
Affiliation
  • Luo HY; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Gao LC; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Long HZ; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China. 89206346@qq.com.
  • Zhou ZW; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China. 89206346@qq.com.
  • Xu SG; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Li FJ; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Li HL; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Cheng Y; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Li CX; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Peng XY; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Li L; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
  • Chen R; Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Changsha, 410004, China.
  • Deng P; School of Pharmacy, Department of Pharmacy, Phase I Clinical Trial Centre, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, China.
Eur J Clin Pharmacol ; 79(5): 663-670, 2023 May.
Article in En | MEDLINE | ID: mdl-36976322
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neprilysin / Heart Failure / Hypotension Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Eur J Clin Pharmacol Year: 2023 Document type: Article Affiliation country: China Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neprilysin / Heart Failure / Hypotension Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Eur J Clin Pharmacol Year: 2023 Document type: Article Affiliation country: China Country of publication: Germany